UnitedHealth shares surge as Buffett’s Berkshire shows new stake

UnitedHealth Group (UNH) shares surged 7% after-hours following Berkshire Hathaway's disclosure of a new 5 million share stake, valued at $1.37 billion, in the healthcare provider. This significant investment by Warren Buffett's firm, revealed in its latest portfolio update, signals a notable vote of confidence despite UNH's substantial year-to-date decline and ongoing operational challenges. The filing also detailed Berkshire's broader strategic shifts, including new positions in Nucor, DR Horton, Allegion, and Lamar Advertising, alongside reduced stakes in Apple and Bank of America, and increased holdings in Chevron and others.

Analysis

UnitedHealth Group (UNH) shares experienced a significant 7% after-hours surge following the disclosure of a new 5 million share stake by Berkshire Hathaway, valued at $1.37 billion. This investment serves as a powerful vote of confidence from a highly respected institutional investor, especially given that UNH has been under considerable pressure, with its stock down 46% year-to-date. The company's recent challenges are substantial, including disappointing second-quarter results, lowered guidance, surging medical expenses, ongoing federal probes, the aftermath of a cyberattack, and the death of an executive. Berkshire's move to initiate a position amidst these headwinds suggests a classic value-investing thesis, capitalizing on market pessimism. It is crucial to note, however, that the filing reflects holdings as of the end of the second quarter of 2025 and the position could have been altered since. The disclosure also revealed Berkshire's broader portfolio adjustments, including a liquidation of its T-Mobile stake and reduced positions in Apple and Bank of America, indicating wider strategic shifts.

Key Decisions for Investors

• Investors should interpret Berkshire Hathaway's new stake as a strong contrarian signal, suggesting that UnitedHealth's 46% year-to-date stock decline may present a favorable risk-reward profile despite its well-publicized operational challenges.
• It remains critical to monitor the specific headwinds affecting the company, particularly the trajectory of medical expenses and the outcomes of federal probes, as these fundamental factors will be key drivers of performance beyond the initial sentiment boost.
• Acknowledge that the 7% after-hours rally has already priced in the disclosure, and consider that Berkshire's position reflects a past holding which could have been modified in the intervening period.